Table 2.
Baseline characteristics of the 13 patients who achieved the primary endpoint of the study.
| Age (years) | Sex (F/M) | Centre | PPMS or SPMS | MS duration (years) | Baseline EDSS | Improvement | DMT | |
|---|---|---|---|---|---|---|---|---|
| EDSS | TW25 | |||||||
| 68 | M | 1 | PPMS | 3.0 | 6.5 | + | – | |
| 50 | M | 1 | SPMS | 14.0 | 6.5 | – | + | |
| 52 | M | 2 | PPMS | 6.0 | 6.5 | + | – | MPM |
| 63 | F | 3 | SPMS | 12.0 | 4.5 | + | – | INF |
| 55 | M | 6 | SPMS | 18.0 | 7 | – | + | |
| 43 | M | 6 | SPMS | 10.0 | 5.5 | + | + | CP |
| 52 | F | 9 | SPMS | 16.0 | 6.5 | + | – | MPM |
| 59 | M | 11 | SPMS | 12.0 | 7 | + | – | MPM |
| 62 | M | 11 | PPMS | 37.0 | 4.5 | + | – | MTX |
| 43 | M | 14 | PPMS | 5.0 | 4.5 | + | – | |
| 64 | M | 14 | SPMS | 31.0 | 6.5 | + | + | |
| 46 | F | 15 | SPMS | 15.0 | 4.5 | + | – | INF |
| 46 | M | 16 | SPMS | 25.0 | 5.5 | – | + | |
| Mean 54.0 | 23.1% F | – | 69.2% SPMS | Mean 15.7 | Mean 5.81 | 76.9% | 38.5% | 53.8% |
CP: cyclophosphamide; DMT: disease-modifying therapy; F: female; EDSS: Expanded Disability Status Scale; INF: interferon; M: male; MPM: mycophenolate mofetil; MS: multiple sclerosis; MTX: methotrexate; PPMS: primary progressive multiple sclerosis; SPMS: secondary progressive multiple sclerosis; TW25: timed 25-foot walk.